US pursues nearly $13 billion of claims in Purdue Pharma opioid probes, sources say | The Business Standard
Skip to main content
  • Home
  • Economy
    • Aviation
    • Banking
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Food
    • Habitat
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wheels
  • Epaper
    • GOVT. Ad
  • More
    • Subscribe
    • Videos
    • TBS Graduates
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Long Read
    • Interviews
    • Offbeat
    • Tech
    • Magazine
  • বাংলা
The Business Standard

Thursday
December 07, 2023

Sign In
Subscribe
  • Home
  • Economy
    • Aviation
    • Banking
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Food
    • Habitat
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wheels
  • Epaper
    • GOVT. Ad
  • More
    • Subscribe
    • Videos
    • TBS Graduates
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Long Read
    • Interviews
    • Offbeat
    • Tech
    • Magazine
  • বাংলা
THURSDAY, DECEMBER 07, 2023
US pursues nearly $13 billion of claims in Purdue Pharma opioid probes, sources say

Global Economy

Reuters
05 August, 2020, 11:45 am
Last modified: 05 August, 2020, 11:52 am

Related News

  • Yemen's Houthis say they launched ballistic missiles at Israel
  • US restricts visas for Uganda, Zimbabwe officials, citing repression
  • Man stabs four to death in New York, police shoot him dead
  • Bangladesh could be target of US labour policy, warns Washington mission
  • Minnesota students exchange with Bangladeshi students about US education opportunities

US pursues nearly $13 billion of claims in Purdue Pharma opioid probes, sources say

The size of the claims represent the upper limit of penalties federal prosecutors might seek, and the ultimate sums paid to resolve the investigations are likely to be far lower, the people said

Reuters
05 August, 2020, 11:45 am
Last modified: 05 August, 2020, 11:52 am
A pharmacist holds prescription painkiller OxyContin, 40mg pills, made by Purdue Pharma L.D. at a local pharmacy, in Provo, Utah, US, April 25, 2017. Photo:Reuters
A pharmacist holds prescription painkiller OxyContin, 40mg pills, made by Purdue Pharma L.D. at a local pharmacy, in Provo, Utah, US, April 25, 2017. Photo:Reuters

US prosecutors are pursuing possible penalties of nearly $13 billion to resolve investigations of OxyContin maker Purdue Pharma after uncovering evidence of criminal and civil misconduct stemming from the company's alleged role in fueling the nation's opioid crisis, people familiar with the matter said.

US Justice Department officials outlined additional details of their ongoing investigations of the company, controlled by the wealthy Sackler family, in paperwork filed last week with a federal bankruptcy court in White Plains, NY, which has not yet become public, the people said.

As with other Purdue creditors, the Justice Department had to meet a July 30 deadline to assert financial claims against the company. The initial claims seek about $10 billion in criminal penalties, consisting of a fine exceeding $6 billion and a forfeiture of more than $3 billion, as well as a civil penalty of nearly $3 billion, one of the people said.

The Business Standard Google News Keep updated, follow The Business Standard's Google news channel

The size of the claims represent the upper limit of penalties federal prosecutors might seek, and the ultimate sums paid to resolve the investigations are likely to be far lower, the people said.

The Justice Department is among thousands of creditors vying to extract money from Purdue, which has a liquidation value of only a bit more than $2 billion. Purdue has offered to settle widespread opioid litigation in a deal it values at more than $10 billion.

That includes $3 billion from the Sacklers and value derived from the Stamford, Connecticut-based firm transforming into a public benefit company run on behalf of plaintiffs that would donate addiction treatment drugs and opioid overdose-reversal medications under development.

Purdue filed for bankruptcy protection nearly a year ago and received court approval to halt more than 2,600 lawsuits brought by cities, counties, states, hospitals and other plaintiffs alleging the company and the Sacklers were major contributors to the US opioid epidemic. The company and family have denied the allegations.

As part of the criminal probe, Justice Department officials are scrutinizing Purdue's alleged encouragement of illegal opioid prescriptions, some of the people said. US prosecutors are focused on possible conspiracy charges and alleged violations of anti-kickback and drug safety laws, they said.

A separate civil investigation is focused in part on the company's alleged defrauding of government healthcare programs such as Medicare, one of the people said.

Justice Department officials and lawyers for the company and family have held discussions about resolving the probes and details, including the size of any financial penalties prosecutors might seek, could change, the people said.

Neither Purdue nor the Sacklers have currently been charged with criminal wrongdoing or civil violations in the Justice Department investigations, and federal prosecutors have not yet decided whether to bring cases, they said.

Purdue said it is cooperating with the Justice Department probes and in discussions to resolve them, but declined to comment further. A lawyer for the Raymond Sackler family said the family acted ethically and responsibly at all times, but declined to comment on the Justice Department's filings. Representatives for another group of Sacklers had no immediate comment.

A Justice Department spokeswoman declined to comment.

Purdue has been in the Justice Department's crosshairs before, when the company and three executives pleaded guilty in 2007 to charges of misbranding OxyContin to resolve a case that also included more than $600 million in penalties.

The Justice Department's current claims could significantly affect ongoing settlement discussions among Purdue, the Sacklers, and thousands of US communities that have sued the company and family. Plaintiffs are seeking billions of dollars in damages to address harm from opioids.

Resolving the Justice Department probes is a condition of Purdue's proposed settlement, and penalties US officials seek could affect how much money plaintiffs receive to address a public health crisis that claimed the lives of nearly 450,000 people between 1999 and 2018, according to the latest US data.

The lawsuits against Purdue and, in some cases, the Sacklers allege they aggressively marketed prescription painkillers while misleading doctors and patients about their addiction and overdose risks.

Purdue has said US Food and Drug Administration-approved labels for the company's opioids carried warnings about risk and abuse associated with treating pain. Purdue and the Sacklers have denied allegations in lawsuits that they contributed to the opioid crisis, and have pointed to heroin and fentanyl as more significant culprits than prescription painkillers.

Health experts have said many people turned to drugs like heroin only after first becoming addicted to prescription opioids.

More than 20 states led by Massachusetts, New York and Connecticut initially objected to the settlement proposal from Purdue and the Sacklers, wanting a larger contribution from the family and more details on their finances. Plaintiffs are currently involved in discussions overseen by court-appointed mediators about how to allocate settlement proceeds.

World+Biz

US

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Ahsan H Mansur. Sketch: TBS
    Bringing down inflation will be extremely challenging: Ahsan H Mansur
  • File photo of Russian Ambassador to Bangladesh Alexander Mantytskiy. During his tenure as the Russian ambassador to Afghanistan he speaks during a news conference at the Russian embassy in Kabul, Afghanistan, April 25, 2016. Photo: REUTERS
    Russia does not recognise 'illegal' sanctions by western countries: Ambassador
  • A video grab shows Bangladesh Institute of Development Studies (BIDS) director Binayak Sen speaking at the inaugural session of the Annual BIDS Conference on Development (ABCD) 2023 on Thursday (7 December)
    We have no reason to trade democracy and freedom of speech for development: Binayak Sen

MOST VIEWED

  • Bangladeshi RMG exporters alarmed as buyers tag conditions over trade restriction fears
    Bangladeshi RMG exporters alarmed as buyers tag conditions over trade restriction fears
  • Illustration: TBS
    Troubled banks categorised, new deposits, loans barred for weakest
  • File Photo of the US Ambassador to Bangladesh Peter Haas. Photo: Collected
    US Ambassador Peter Haas holds meeting with Biman officials
  • Bank deposits in Bangladesh surge on higher interest, lower investment
    Bank deposits in Bangladesh surge on higher interest, lower investment
  • Photo: AFP
    Bangladesh lose 4 wickets after decent start in first session
  • Illustration: TBS
    Cenbank doubles limit for sending remittances to MFS accounts

Related News

  • Yemen's Houthis say they launched ballistic missiles at Israel
  • US restricts visas for Uganda, Zimbabwe officials, citing repression
  • Man stabs four to death in New York, police shoot him dead
  • Bangladesh could be target of US labour policy, warns Washington mission
  • Minnesota students exchange with Bangladeshi students about US education opportunities

Features

Hamas-Israel war: What really happened on 7 October?

Hamas-Israel war: What really happened on 7 October?

8h | Panorama
UN workers arrive to distribute aid to Palestinians, who have fled their homes due to Israeli strikes and take shelter in a UN-run school, in Khan Younis in the southern Gaza Strip on 23 October 2023. Photo: Reuters

When UN and its agencies lack much agency

8h | Panorama
Sketch: TBS

How Khan Farhana built a 300,000-strong LinkedIn community

19h | Pursuit
Photo: Courtesy

Fostering emotional intelligence and classroom harmony: The power of a complaint box

19h | Pursuit

More Videos from TBS

Messi named Time Magazine's 'Athlete of the Year'

Messi named Time Magazine's 'Athlete of the Year'

4h | TBS SPORTS
What is 'obstructing the field' out?

What is 'obstructing the field' out?

23h | TBS SPORTS
When Farooki is hero

When Farooki is hero

22h | TBS Entertainment
Losing uteruses to the climate crisis in coastal Bangladesh

Losing uteruses to the climate crisis in coastal Bangladesh

6h | TBS Stories
EMAIL US
[email protected]
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2023
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - [email protected]

For advertisement- [email protected]